Ensign Peak Advisors Inc lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,909 shares of the medical research company’s stock after selling 213 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.10% of Charles River Laboratories International worth $14,175,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also made changes to their positions in the business. BlackRock Inc. grew its position in shares of Charles River Laboratories International by 4.1% during the 1st quarter. BlackRock Inc. now owns 5,591,211 shares of the medical research company’s stock worth $1,620,503,000 after buying an additional 221,598 shares in the last quarter. FIL Ltd grew its position in shares of Charles River Laboratories International by 9.0% during the 4th quarter. FIL Ltd now owns 810,907 shares of the medical research company’s stock worth $202,613,000 after buying an additional 67,238 shares in the last quarter. King Luther Capital Management Corp grew its position in shares of Charles River Laboratories International by 11.1% during the 1st quarter. King Luther Capital Management Corp now owns 529,554 shares of the medical research company’s stock worth $153,481,000 after buying an additional 52,821 shares in the last quarter. Norges Bank bought a new position in shares of Charles River Laboratories International during the 4th quarter worth $120,525,000. Finally, Mackenzie Financial Corp grew its position in shares of Charles River Laboratories International by 16.5% during the 4th quarter. Mackenzie Financial Corp now owns 429,343 shares of the medical research company’s stock worth $107,276,000 after buying an additional 60,774 shares in the last quarter. 93.87% of the stock is currently owned by institutional investors.
Shares of NYSE:CRL opened at $357.78 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $165.76 and a 52-week high of $359.55. The stock has a market capitalization of $17.98 billion, a PE ratio of 48.48, a price-to-earnings-growth ratio of 2.52 and a beta of 1.14. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.53 and a current ratio of 1.77. The business has a 50-day moving average price of $331.82.
Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Monday, May 3rd. The medical research company reported $2.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.34. Charles River Laboratories International had a return on equity of 22.54% and a net margin of 12.33%. The firm had revenue of $824.60 million during the quarter, compared to analysts’ expectations of $798.52 million. During the same period last year, the business posted $1.84 earnings per share. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. Research analysts expect that Charles River Laboratories International, Inc. will post 9.99 EPS for the current fiscal year.
In related news, VP Birgit Girshick sold 18,311 shares of the firm’s stock in a transaction dated Tuesday, April 6th. The stock was sold at an average price of $302.61, for a total transaction of $5,541,091.71. Following the sale, the vice president now directly owns 30,059 shares of the company’s stock, valued at $9,096,153.99. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael Gunnar Knell sold 800 shares of the firm’s stock in a transaction dated Thursday, June 3rd. The stock was sold at an average price of $329.76, for a total value of $263,808.00. Following the sale, the chief accounting officer now directly owns 4,563 shares in the company, valued at $1,504,694.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,079 shares of company stock worth $15,847,322. 1.20% of the stock is owned by corporate insiders.
A number of equities research analysts recently weighed in on the company. KeyCorp upped their price objective on Charles River Laboratories International from $340.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, May 14th. Robert W. Baird restated a “buy” rating on shares of Charles River Laboratories International in a research note on Monday, May 31st. Morgan Stanley upped their price objective on Charles River Laboratories International from $280.00 to $350.00 and gave the stock an “overweight” rating in a research note on Thursday, February 25th. Truist Securities upped their price objective on Charles River Laboratories International from $324.00 to $369.00 and gave the stock a “buy” rating in a research note on Tuesday, May 25th. Finally, JPMorgan Chase & Co. upped their price objective on Charles River Laboratories International from $375.00 to $390.00 and gave the stock an “overweight” rating in a research note on Friday, May 28th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Charles River Laboratories International has an average rating of “Buy” and a consensus price target of $327.80.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
See Also: What is an investor looking for in an SEC filing?